Company intelligence / Profile preview

Lee Bank

Hong Kong, Hong Kong, China

Ownership: Private
Employees: ~1022
Development stage: Other

Overview

Multiple approved products including prulifloxacin for bronchitis (approved China), recombinant human interferon α2b for herpes zoster (approved), and Adasuve® commercializing in Greater China for acute agitation. Recent acquisition of Staccato® OBT® platform adds Phase 2 assets in Parkinson's and CVS, and Phase 3 Staccato® alprazolam partnership with UCB.

Therapeutic areas: HematologyWomen's HealthOtherCardiovascularNeurologyDermatologyInfectious DiseasesPsychiatryPulmonologyRare DiseasesGastroenterologyOncologyOphthalmology
Modalities: Small moleculeBiological productsInterferonsSynthetic peptide
Industry: Biotech

Partnerships

UCB (global license and supply for Staccato® alprazolam)Around 30 international companies

Beyond the preview

Go deeper on Lee Bank.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lee Bank.

Explore the full profile